Why People Using GLP-1s Are Less Likely to Exercise

Patients initiating GLP-1 medications for weight management, such as Ozempic, Wegovy, and Mounjaro, may experience a decrease in physical activity levels, according to research presented at the Endocrine Society’s annual meeting (ENDO 2026) in Chicago. Data from 753 individuals showed a decline in both daily step counts and moderate-to-vigorous physical activity (MVPA) after starting treatment, with the most significant reductions occurring in males and those suffering from musculoskeletal pain.

Study findings on activity levels

The research team tracked participants using Fitbit activity data to compare behavior before and after the commencement of GLP-1 therapy. On average, daily step counts dropped from 5,047 to 4,487, while daily MVPA minutes fell from 28 to 22. Despite the widely recognized health benefits of weight loss, the study found no evidence that the use of these medications naturally leads to increased physical activity.

Did You Know? The study group consisted of 753 individuals with obesity, of whom 78.6% were female, with an average age of 52.7 years.

Why exercise remains essential

While GLP-1 medications are effective for weight management, experts warn that a reduction in movement can hinder long-term health goals. Mir Ali, MD, medical director of the MemorialCare Surgical Weight Loss Center, noted that patients often report fatigue while losing weight, which may make exercise feel like a chore. According to Ali, failing to maintain activity levels can lead to increased muscle loss, heightened fatigue, and less effective weight loss results overall.

How To START EXERCISE On GLP1 Medication – Dr. G Explains

Expert Insight: The data suggests a potential trade-off where the pharmacological success of weight loss may inadvertently mask the necessity of maintaining physical conditioning. Because GLP-1s can cause fatigue, patients may struggle to meet the recommended goal of 30 minutes of exercise, five days a week. However, maintaining muscle mass through resistance training and aerobic activity remains a critical component of metabolic health that medication alone cannot replace.

What happens next for patients

As these findings highlight the necessity of structured movement, it is likely that clinicians will increasingly emphasize targeted interventions for patients on GLP-1 therapy. Sajana Maharjan, MD, lead author of the study and a board-certified internist at HSHS St. John’s Hospital, stated that exercise cannot be considered optional for those taking these medications. Future clinical management may involve more rigorous tracking of physical activity to ensure patients combine their pharmaceutical treatment with consistent movement to preserve muscle and enhance overall well-being.

Frequently Asked Questions

Who experienced the largest decline in physical activity?
The study observed the greatest decreases in daily step counts and moderate-to-vigorous physical activity among males and individuals experiencing muscle or joint pain.

Did age or heart conditions affect the results?
No. The researchers found that factors such as age, prior stroke, or heart failure did not appear to change the study’s results regarding activity levels.

Is this study published in a peer-reviewed journal?
No. The findings were presented at the Endocrine Society’s annual meeting (ENDO 2026) and have not yet been published in a peer-reviewed journal.

How do you plan to incorporate consistent movement into your daily routine while managing your health goals?